Page last updated: 2024-10-25

ciglitazone and Cardiomyopathies, Primary

ciglitazone has been researched along with Cardiomyopathies, Primary in 1 studies

ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mishra, PK1
Tyagi, N1
Sen, U1
Joshua, IG1
Tyagi, SC1

Other Studies

1 other study available for ciglitazone and Cardiomyopathies, Primary

ArticleYear
Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.
    Cardiovascular diabetology, 2010, Sep-09, Volume: 9

    Topics: Animals; Antioxidants; Cardiomyopathies; Cyclic N-Oxides; Diabetes Complications; Diabetes Mellitus,

2010